Company Zoom Meeting, page-24

My view is that a company other than VM would be advantageous, VM are pets only while a company with human pipelines could provide a smoother transition into human cancer trials. The chances of MPL having efficacy in Humans is solid based on the Canine results so far, and will increase with continuing success in Phase 3. Roger has already said he expects one company will eventually own all the licenses to prevent cross prescribing, and this seems to make sense to me.

Many of the top 50 holders are long term holders who have an average purchase price that is below 10 cents for their 1,000,000 plus shares so the opportunity for serious gains are very real.


Pete